(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Extreme Manual for Purchasing Your Next Truck - 2The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- 3At least 18 Palestinians killed in latest clashes in Gaza
- 4Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
- 5Must-See Attractions in France
- Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon
- UN chief calls on Yemen's Houthi rebels to free all UN detainees
- Finding Your Motivation: Moves toward a Satisfying Life
- What to know as New York City nurses strike for a 3rd day
- 5 Most Expected Film Delivery
- Empathy and reasoning aren’t rivals – new research shows they work together to drive people to help more
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- The Force of Care: Living with Goal
